Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease

Xu, Rui‐Xia; Zhang, Yan; Li, Xin; Li, Sha; Guo, Yuan‐Lin; Dong, Qian; Li, Geng; Li, Jianjun

doi:10.1016/j.cca.2015.04.032

Cited by 8 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result is partially consistent with the findings of previous studies [40,41]. Some studies found that Lp-PLA2 levels correlated positively with TC but correlated negatively with HDL-C levels [40][41][42]. However, we did not observe such correlations in the present study.…”

Section: Discussioncontrasting

confidence: 34%

Synergistic Effect of Lipoprotein-Associated Phospholipase A2 with Classical Risk Factors on Coronary Heart Disease: A Multi-Ethnic Study in China

Chen²,

Pan³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

Aims: We evaluated the synergistic effect of lipoprotein-associated phospholipase A2 (Lp-PLA2) in association with classical risk factors in predicting coronary heart disease (CHD) and demonstrated the diagnostic value of Lp-PLA2 for predicting coronary stenotic lesions in subjects with CHD. Methods: Blood samples were acquired from 911 consecutive adult subjects (662 males and 249 females) from 11 ethnic groups. Lp-PLA2 plasma levels were detected using a commercially available turbidimetric immunoassay (TIA). CHD in patients was confirmed using coronary angiography, and the severity of coronary atherosclerosis was assessed using the Gensini scoring system. Results: A binary logistic regression was performed to analyse the relationships between Lp-PLA2 and other risk factors. A multivariate logistic regression analysis revealed that Lp-PLA2 levels were significantly associated with CHD (OR, 1.882; 95% CI, 1.369-2.587, p=0.000).The area under the receiver operating characteristic curve for Lp-PLA2 was 0.589 (95%CI, 0.549-0.629, p=0.000).The synergism between Lp-PLA2 and other risk factors was also investigated. The proportion of CHD attributable to the interaction between Lp-PLA2 and age was as high as 64%. Conclusions: Lp-PLA2 levels in human plasma were positively associated with the severity of CHD, and there was a clear positive interaction between Lp-PLA2 and classical risk factors in predicting CHD.

show abstract

Section: Discussioncontrasting

confidence: 34%

Synergistic Effect of Lipoprotein-Associated Phospholipase A2 with Classical Risk Factors on Coronary Heart Disease: A Multi-Ethnic Study in China

Chen²,

Pan³

et al. 2016

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Apolipoprotein A-1 (apoA-1) comprises nearly 70% of the apolipoproteins on the HDL particles, allowing an effective calculation of HDL concentration. Meanwhile, there is a definite connection between Lp-PLA2 level and LDL-cholesterol concentration whereas negatively related to HDL-cholesterol concentration [ 12 , 13 ]. Consequently, understanding the relation between Lp-PLA2 and apolipoprotein may suggest several potential determinants with regard to the risk of CAD.…”

Section: Introductionmentioning

confidence: 99%

Relationship between Plasma Lipoprotein-Associated Phospholipase A2 Concentrations and Apolipoprotein in Stable Coronary Artery Disease Patients

Yang¹,

Tang²,

Cao

et al. 2020

Disease Markers

View full text Add to dashboard Cite

Background. Increasing evidence states that the plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) levels and apolipoprotein particles are regarded as the risk maker for cardiovascular heart disease. Nevertheless, the issue about whether Lp-PLA2 is associated with apolipoprotein particles in individuals who have been diagnosed as stable coronary artery disease (CAD) remains largely unexplored. Method. All 569 participants engaged in this research, who never took lipid-lowering drugs, had been divided into groups by the coronary angiography (CAG), namely, stable CAD: n=291; non-CAD: n=278. The results concerning Lp-PLA2 levels were calculated by Elisa Kit, while apolipoprotein particles were measured by the department of laboratory. Results. The plasma concentration of Lp-PLA2 was remarkably higher in stable CAD group than the non-CAD group (136.0±60.5 ng/mL vs. 113.2±65.6 ng/mL, P<0.001). Pearson correlation analyses explained the plasma Lp-PLA2 concentration was correlated with apoB (r=0.390, P<0.001) and apoB/apoA1 (r=0.450, P<0.001), not associated with apoA1 (r=−0.099, P=0.101). Conversely, the association remains unobserved among non-CAD patients except apoA1. Moreover, multiple linear regression revealed the relations between Lp-PLA2 concentrations and apoB (β=0.390, P<0.001), as well as apoB/apoA1 (β=0.450, P<0.001), but not apoA1 (β=−0.099, P=0.121). After adjustment for several risk factors regarding CAD, like hypertension, gender, smoking, age, and diabetes mellitus, there had still been positive associations between the Lp-PLA2 concentration and apoB (β=0.364, P<0.001), as well as apoB/apoA1 (β=0.390, P<0.001). Conclusion. The plasma levels of Lp-PLA2 provide positively a key link with apoB, apoB/apoA-1 among stable CAD, denoting the communication between Lp-PLA2 and apolipoprotein particles in the state of CAD.

show abstract

“…Lp-PLA2 exhibits a strong connection with the development and advancement of DM microvascular complications [ 28 ]. Furthermore, when contrasted with other complications stemming from diabetes, the link between diabetic nephropathy (DN) and Lp-PLA2 stands out as notably prominent [ 29 ]. Recent research findings additionally indicate that Lp-PLA2 operates as an autonomous variable when evaluating early DN, potentially serving as a crucially specific marker for diagnosing this condition in its initial stages [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Serum levels of lipoprotein-associated phospholipase A2 are associated with coronary atherosclerotic plaque progression in diabetic and non-diabetic patients

Zhang,

Wang,

Chen

et al. 2024

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Lp-PLA2 is linked to cardiovascular diseases and poor outcomes, especially in diabetes, as it functions as a pro-inflammatory and oxidative mediator. Objectives This research aimed to explore if there is a connection between the serum levels of Lp-PLA2 and the progression of coronary plaques (PP) in individuals with type 2 diabetes mellitus (T2DM) and those without the condition. Materials and methods Serum Lp-PLA2 levels were measured in 137 T2DM patients with PP and 137 T2DM patients with no PP, and in 205 non-diabetic patients with PP and 205 non-diabetic patients with no PP. These individuals met the criteria for eligibility and underwent quantitative coronary angiography at the outset and again after about one year of follow-up. The attributes and parameters of the participants at the outset were recorded. Results Increased serum levels of Lp-PLA2 were closely associated with coronary artery PP, and also significantly correlated with change of MLD, change of diameter stenosis and change of cumulative coronary obstruction in both diabetic and non-diabetic groups, with higher correlation coefficients in diabetic patients as compared with non-diabetic patients. Moreover, multivariate logistic regression analysis showed that serum Lp-PLA2 level was an independent determinant of PP in both groups, with OR values more significant in diabetic patients than in non-diabetic patients. Conclusions Levels of serum Lp-PLA2 show a significant association with the progression of coronary atherosclerotic plaque in patients with T2DM and those without, especially among individuals with diabetes.

show abstract

Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease

Cited by 8 publications

References 33 publications

Synergistic Effect of Lipoprotein-Associated Phospholipase A2 with Classical Risk Factors on Coronary Heart Disease: A Multi-Ethnic Study in China

Synergistic Effect of Lipoprotein-Associated Phospholipase A2 with Classical Risk Factors on Coronary Heart Disease: A Multi-Ethnic Study in China

Relationship between Plasma Lipoprotein-Associated Phospholipase A2 Concentrations and Apolipoprotein in Stable Coronary Artery Disease Patients

Serum levels of lipoprotein-associated phospholipase A2 are associated with coronary atherosclerotic plaque progression in diabetic and non-diabetic patients

Contact Info

Product

Resources

About